If you or someone in your family has tested positive for a BRCA gene, you may know that you're at an increased risk of developing certain cancers including breast, ovarian, pancreatic, and melanoma. BRCA positive men have an increased risk of prostate cancer and breast cancer as well.
However, a positive genetic test result cannot determine if you will actually develop cancer.
That’s why a routine and effective way of detecting cancer mutations early is especially critical for people managing BRCA diagnosis, or family members with BRCA1 or BRCA2 mutations.
Serenity is the first test that helps guide physicians in detecting 8 cancers, including breast cancer, at early stages in the blood. In fact, Serenity can precisely identify a single molecule of cancer DNA. So you can take a proactive approach with routine monitoring of BRCA mutations.
Finally, take your health into your own hands. Be the first to know when Serenity is available.
Serenity has been studied in one of the largest cfDNA clinical trials across 15 cancer types and 13 leading oncology centers in the US, Germany, and Switzerland.
From answering questions to interpreting your results, Serenity is by your side with expert physician support.
Serenity combines precision sequencing with artificial intelligence to detect very small traces of cancer-related mutations in the blood. This is a new way to screen for cancer using cell-free DNA (cfDNA) from a simple blood draw.
Sign up now to take control of your health with the world's first blood test for early cancer detection.